Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript
Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript
Stock Taper 
CNSY
$1.56
▼ DOWN 2.50% (-0.04)
KEY STATISTICS
Market Cap$10.67 M
52w High$21.50
52w Low$1.49
Dividend Yield—
Frequency—
P/E-0.37
Volume222.87K
Shares Out.6.88M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Marc H. Hedrick
ABOUT
SECTOR
Healthcare
WENT PUBLIC
August 3, 2026
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
28
UPCOMING EARNINGS
DateOct 15, 2026
DayThursday
Rev. Est.$750.00K
OCT
15
THU
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-04-02 | Reverse | 1:25 |
| 2023-05-01 | Reverse | 1:15 |
| 2019-08-06 | Reverse | 1:50 |
| 2018-05-24 | Reverse | 1:10 |
| 2016-05-12 | Reverse | 1:15 |
ETFS HOLDING THIS STOCK
ETFS HOLDING
12
LISTED HERE
2
RANKED BY POSITION SIZE
PRICE
$1.56 ▼ DOWN 2.50% (−$0.04)About Cerenome, Inc.
http://www.plustherapeutics.com ↗Plus Therapeutics, Inc., a Houston-based clinical-stage pharma company founded in 1996, develops chemotherapeutics and radiotherapeutics like Rhenium NanoLiposome and DocePLUS for rare cancers with unmet medical needs.
INDUSTRY
Medical - Pharmaceuticals
A PRODUCT CERENOME, INC. IS KNOWN FOR
CNSide® Diagnostic
CNSide® is a reimbursed diagnostic platform that analyzes cerebrospinal fluid to detect and characterize CNS cancer cells, aiding diagnosis, monitoring, and treatment guidance within Cerenome's CNS oncology approach.
Cerenome in 2025
SENTIMENT: + POSITIVE
INNOVATION · AUGUST 2025
Cerenome (formerly Plus Therapeutics) Announces Positive Phase 1 Data for REYOBIQ™ in Treating Leptomeningeal Metastases, Showing High Clinical Benefit Rate
In August 2025, the company, then known as Plus Therapeutics, presented highly positive results from its ReSPECT-LM Phase 1 trial for REYOBIQ™ in patients with leptomeningeal metastases. The data, presented at the SNO/ASCO CNS Metastases Conference, showed a clinical benefit rate of over 75% and a median overall survival of 9 months, a significant improvement over the typical 4-month survival, causing a surge in investor interest due to the treatment's potential in this hard-to-treat cancer.
— · N/A · —
No single, most significant strategic shift identified in 2025
Based on available public information, Cerenome, Inc. (then Plus Therapeutics, Inc.) did not announce a singular, defining strategic shift in 2025. The company was primarily focused on executing its clinical trials for its REYOBIQ therapeutic and advancing its CNSide diagnostic platform. The most significant strategic transformation, the rebranding to Cerenome and the formal pivot to an integrated diagnostics, therapeutics, and AI-driven CNS oncology company, was publicly announced and initiated in mid-2026.
Latest News
EARLIER COVERAGE
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today provided a third quarter 2026 business update for its wholly owned subsidiary, CNSide Diagnostics, LLC, highlighting gross payer billings, progress on Medicare coverage of its Tumor Cell Enumeration Test (TCE Test) and the expansion of the CNSide testing menu.
RATINGS SNAPSHOT
Overall rating: C-
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book2
Overall Score1
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
INSIDER TRADES
★
DIRECTOR
Guse Kyle
Sale · 921 shares
2026-10-01
★
DIRECTOR
Guse Kyle
Purchase · 921 shares
2026-10-01
★
DIRECTOR
ANDREWS RONALD ASBURY
Sale · 921 shares
2026-10-01
★
DIRECTOR
ANDREWS RONALD ASBURY
Purchase · 921 shares
2026-10-01